Akebia Therapeutics, Inc. (AKBA) vs Bio-Rad Laboratories, Inc. (BIO)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| AKBA | BIO | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Medical Devices |
| Size band | SMALL | MID |
| Listing | Nasdaq CM | NYSE |
| Country | United States | United States |
| Theme | rare-disease | life-science-tools |
| Price and returns | ||
| Last close | $0.64 | $372.43 |
| Return · 1 week | −5.32% | +5.56% |
| Return · 1 month | −27.91% | −1.39% |
| Return · 3 months | −49.31% | +12.52% |
| Return · year to date | −58.46% | +22.00% |
| Return · 1 year | −79.69% | +10.80% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −79.88% | −6.01% |
| 52-week high | $3.20 | $396.23 |
| 52-week low | $0.54 | $236.73 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $178.40M | $9.97B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $4.77M | $93.82M |
| Employees | 194 | 7,450 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 46.41× |
| Price to earnings · forward | n/a (negative forward earnings) | 36.92× |
| Price to sales | 1.01× | 3.78× |
| Price to book | 8.71× | 1.36× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 21.75× |
| Enterprise value to revenue | 1.30× | 3.70× |
| PEG ratio | — | 4.01 |
| Earnings per share · trailing | -0.12 | 7.89 |
| Profitability | ||
| Gross margin | 79.63% | 51.90% |
| Operating margin | −5.46% | 11.18% |
| Profit margin | −13.54% | 8.59% |
| Return on equity | −109.38% | 3.11% |
| Return on assets | −1.05% | 1.66% |
| Growth | ||
| Revenue growth | −21.40% | −0.10% |
| Earnings growth | — | +18.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | 796.18 | 19.10 |
| Current ratio | 1.43 | 3.14 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | — | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 35.08 | 54.82 |
| ADX · 14 | 33.65 | 17.76 |
| 50-day average | $0.86 | $373.32 |
| 200-day average | $1.16 | $312.23 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 8.40% | 3.00% |
The full AKBA analysis
Everything this table leaves out for Akebia Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AKBA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AKBA analysisThe full BIO analysis
Everything this table leaves out for Bio-Rad Laboratories, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BIO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BIO analysis